Matches in SemOpenAlex for { <https://semopenalex.org/work/W2490508719> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- W2490508719 endingPage "58" @default.
- W2490508719 startingPage "58" @default.
- W2490508719 abstract "Most women who are diagnosed with endometrial carcinoma present at an early stage and are usually cured of their disease by surgery with or without adjuvant radiation therapy and/or chemotherapy. For those patients who present with advanced disease or develop recurrent disease, survival is greatly diminished. Chemotherapy plays an important role in the management of these patients. Doxorubicin is one of the most active chemotherapy drugs in the advanced or recurrent setting, with response rates in the order of 25%. The use of doxorubicin is limited by its cumulative dose-dependent cardiotoxicity. Pegylated liposomal doxorubicin is a newer formulation of conventional doxorubicin. Its altered pharmacokinetics result in a longer half-life, decreased exposure in healthy tissues, and enhanced delivery of the active drug to the tumor bed. Pegylated liposomal doxorubicin has a relatively milder toxicity profile and a lower incidence of cardiac adverse events. In this article the data on the use of pegylated liposomal doxorubicin in advanced or recurrent endometrial cancer, including the serous papillary histologic variant, are reviewed." @default.
- W2490508719 created "2016-08-23" @default.
- W2490508719 creator A5040266917 @default.
- W2490508719 creator A5073112596 @default.
- W2490508719 date "2011-01-01" @default.
- W2490508719 modified "2023-09-26" @default.
- W2490508719 title "Treating Endometrial Adenocarcinoma—Do Data Support the Use of Pegylated Liposomal Doxorubicin?" @default.
- W2490508719 doi "https://doi.org/10.17925/ohr.2011.07.1.58" @default.
- W2490508719 hasPublicationYear "2011" @default.
- W2490508719 type Work @default.
- W2490508719 sameAs 2490508719 @default.
- W2490508719 citedByCount "0" @default.
- W2490508719 crossrefType "journal-article" @default.
- W2490508719 hasAuthorship W2490508719A5040266917 @default.
- W2490508719 hasAuthorship W2490508719A5073112596 @default.
- W2490508719 hasBestOaLocation W24905087191 @default.
- W2490508719 hasConcept C126322002 @default.
- W2490508719 hasConcept C2776694085 @default.
- W2490508719 hasConcept C2781303535 @default.
- W2490508719 hasConcept C71924100 @default.
- W2490508719 hasConceptScore W2490508719C126322002 @default.
- W2490508719 hasConceptScore W2490508719C2776694085 @default.
- W2490508719 hasConceptScore W2490508719C2781303535 @default.
- W2490508719 hasConceptScore W2490508719C71924100 @default.
- W2490508719 hasIssue "01" @default.
- W2490508719 hasLocation W24905087191 @default.
- W2490508719 hasOpenAccess W2490508719 @default.
- W2490508719 hasPrimaryLocation W24905087191 @default.
- W2490508719 hasRelatedWork W1751946195 @default.
- W2490508719 hasRelatedWork W2023810407 @default.
- W2490508719 hasRelatedWork W2029996357 @default.
- W2490508719 hasRelatedWork W2064009739 @default.
- W2490508719 hasRelatedWork W2073498982 @default.
- W2490508719 hasRelatedWork W2110106434 @default.
- W2490508719 hasRelatedWork W2123574812 @default.
- W2490508719 hasRelatedWork W2247789451 @default.
- W2490508719 hasRelatedWork W2358926017 @default.
- W2490508719 hasRelatedWork W2484974417 @default.
- W2490508719 hasRelatedWork W2626415838 @default.
- W2490508719 hasRelatedWork W2734790071 @default.
- W2490508719 hasRelatedWork W2911529592 @default.
- W2490508719 hasRelatedWork W2969154915 @default.
- W2490508719 hasRelatedWork W3030786822 @default.
- W2490508719 hasRelatedWork W3093306906 @default.
- W2490508719 hasRelatedWork W2850519810 @default.
- W2490508719 hasRelatedWork W2916297688 @default.
- W2490508719 hasRelatedWork W2923649028 @default.
- W2490508719 hasRelatedWork W2925717331 @default.
- W2490508719 hasVolume "07" @default.
- W2490508719 isParatext "false" @default.
- W2490508719 isRetracted "false" @default.
- W2490508719 magId "2490508719" @default.
- W2490508719 workType "article" @default.